Market Place
Sourcing Support
Poxel Reports Q2 And H1 2024 Revenue, Provides Corporate Update
09 Sep 2024 //
BUSINESSWIRE
Poxel Updates Q2 Financials Reschedules Annual General Meeting
15 Jul 2024 //
BUSINESSWIRE
Poxel to Report Its 2023 Annual Results by the End of April 2024
28 Mar 2024 //
BUSINESSWIRE
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA
03 Oct 2022 //
BUSINESSWIRE
Poxel Reports Financial Results for First Half 2022 & Provides Corporate Update
21 Sep 2022 //
BUSINESSWIRE
IMEGLIMIN with Novell Process IMEGLIMIN
22 Aug 2022 //
PRESS RELEASE
Poxel Announces Product Launch in Japan for TWYMEEG as Treatment for T2D
10 Sep 2021 //
BIOSPACE
Vivek Ramaswamy’s Metavant hits a brick wall
20 Nov 2020 //
ENDPTS
Poxel posts phase 3 diabetes data ahead of approval decision
24 Sep 2020 //
FIERCE BIOTECH
Poxel Presents Imeglimin PhIII Results & PXL770 Preclinical Cardio-Renal Results
23 Sep 2020 //
BUSINESSWIRE
Poxel Reports Financial Results for First Half 2020
15 Sep 2020 //
BUSINESSNEWS WIRE
Poxel, Sumitomo Pharma Announce +Ve Phase 3 Results from TIMES 2 Trial
20 Dec 2019 //
BUSINESSWIRE
Poxel and Sumitomo Dainippon Pharma Announce Positive Results for Imeglimin Ph 3
26 Jun 2019 //
BIOSPACE
Poxel & Sumitomo Dainippon Announce Positive Top-Line Results for Imeglimin ph3
09 Apr 2019 //
BUISNESSWIRE
Poxel Completes Patient Enrollment in Ph3 Trial for Imeglimin in Japan
04 Jul 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.